Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones.

There is uncertainty about the site(s) of action of the antidiabetic thiazolidinediones (TZDs). These drugs are agonist ligands of the transcription factor PPAR gamma, which is abundant in adipose tissue but is normally present at very low levels in liver and muscle. We have studied the effects of TZDs in A-ZIP/F-1 mice, which lack white adipose tissue. The A-ZIP/F-1 phenotype strikingly resembles that of humans with severe lipoatrophic diabetes, including the lack of fat, marked insulin resistance and hyperglycemia, hyperlipidemia, and fatty liver. Rosiglitazone or troglitazone treatment did not reduce glucose or insulin levels, suggesting that white adipose tissue is required for the antidiabetic effects of TZDs. However, TZD treatment was effective in lowering circulating triglycerides and increasing whole body fatty acid oxidation in the A-ZIP/F-1 mice, indicating that this effect occurs via targets other than white adipose tissue. A-ZIP/F-1 mice have markedly increased liver PPAR gamma mRNA levels, which may be a general property of fatty livers. Rosiglitazone treatment increased the triglyceride content of the steatotic livers of A-ZIP/F-1 and ob/ob mice, but not the "lean" livers of fat-transplanted A-ZIP/F-1 mice. In light of this evidence that rosiglitazone acts differently in steatotic livers, the effects of rosiglitazone, particularly on hepatic triglyceride levels, should be examined in humans with hepatic steatosis.

[1]  B. Spiegelman,et al.  Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. , 1996, The Journal of clinical investigation.

[2]  J. Bilakovics,et al.  A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. , 2000, Molecular endocrinology.

[3]  K. Moulder,et al.  Sulfated Glycans Stimulate Endocytosis of the Cellular Isoform of the Prion Protein, PrPC, in Cultured Cells (*) , 1995, The Journal of Biological Chemistry.

[4]  D. Lockwood,et al.  Impaired Glucose Tolerance is Normalized by Treatment With the Thiazolidinedione Troglitazone , 1997, Diabetes Care.

[5]  R. Evans,et al.  Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency , 2000 .

[6]  S. Aizawa,et al.  PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. , 1999, Molecular cell.

[7]  Sander Kersten,et al.  Roles of PPARs in health and disease , 2000, Nature.

[8]  M. Olive,et al.  Life without white fat: a transgenic mouse. , 1998, Genes & development.

[9]  J. A. McLean,et al.  Animal and human calorimetry: Preface , 1988 .

[10]  M. Lazar,et al.  Peroxisome Proliferator-Activated Receptor γ1 Expression Is Induced during Cyclic Adenosine Monophosphate-Stimulated Differentiation of Alveolar Type II Pneumonocytes. , 1997, Endocrinology.

[11]  E. Kraegen,et al.  A New Antidiabetic Agent, BRL 49653, Reduces Lipid Availability and Improves Insulin Action and Glucoregulation in the Rat , 1994, Diabetes.

[12]  J. Lehmann,et al.  A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  O. Gavrilova,et al.  Lack of responses to a beta3-adrenergic agonist in lipoatrophic A-ZIP/F-1 mice. , 2000, Diabetes.

[14]  T. Pineau,et al.  Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators , 1995, Molecular and cellular biology.

[15]  C. Newgard,et al.  Direct antidiabetic effect of leptin through triglyceride depletion of tissues. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Hammer,et al.  Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy , 1999, Nature.

[17]  R. Unger.  Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications , 1995, Diabetes.

[18]  Julio E. Pérez,et al.  Cardiac and Glycemic Benefits of Troglitazone Treatment in NIDDM , 1997, Diabetes.

[19]  G. Shulman,et al.  Mechanism of Insulin Resistance in A-ZIP/F-1 Fatless Mice* , 2000, The Journal of Biological Chemistry.

[20]  J. Olefsky.  Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonists , 2000 .

[21]  J. Hoofnagle,et al.  Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes , 2000, Annals of Internal Medicine.

[22]  R. Saladin,et al.  Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. , 2000, Biochemical and biophysical research communications.

[23]  Oksana Gavrilova,et al.  Hormones: Leptin and diabetes in lipoatrophic mice , 2000, Nature.

[24]  K. Umesono,et al.  Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. , 1998, The Journal of clinical investigation.

[25]  L. Moore,et al.  The Pregnane X Receptor: A Promiscuous Xenobiotic Receptor That Has Diverged during Evolution , 2000 .

[26]  X. Shen,et al.  Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. , 2000, Diabetes.

[27]  B. Spiegelman,et al.  PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro , 1999 .

[28]  B. Spiegelman,et al.  mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. , 1994, Genes & development.

[29]  C. Burant,et al.  Troglitazone action is independent of adipose tissue. , 1997, The Journal of clinical investigation.

[30]  T. Burris,et al.  PPARgamma activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes. , 1999, Biochemical and biophysical research communications.

[31]  T. Kadowaki,et al.  Insights into insulin resistance and type 2 diabetes from knockout mouse models. , 2000, The Journal of clinical investigation.

[32]  M. Rao,et al.  Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. , 1993, The Journal of biological chemistry.

[33]  B. Spiegelman,et al.  PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. , 1999, Molecular cell.

[34]  H. Yoo-Warren,et al.  Identification of a DNA clone to phosphoenolpyruvate carboxykinase (GTP) from rat cytosol. Alterations in phosphoenolpyruvate carboxykinase RNA levels detectable by hybridization. , 1981, The Journal of biological chemistry.

[35]  Satoshi Tanaka,et al.  PPARγ Mediates High-Fat Diet–Induced Adipocyte Hypertrophy and Insulin Resistance , 1999 .

[36]  G. Shulman,et al.  Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. , 2000, The Journal of clinical investigation.

[37]  P. Galtier,et al.  Peroxisome Proliferator-activated Receptor α-Isoform Deficiency Leads to Progressive Dyslipidemia with Sexually Dimorphic Obesity and Steatosis* , 1998, The Journal of Biological Chemistry.

[38]  U. Edvardsson,et al.  Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice. , 1999, Journal of lipid research.

[39]  R. Hammer,et al.  Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. , 1996, The Journal of clinical investigation.

[40]  J. Olefsky,et al.  Skeletal muscle peroxisome proliferator- activated receptor-gamma expression in obesity and non- insulin-dependent diabetes mellitus. , 1998, The Journal of clinical investigation.

[41]  R. Hammer,et al.  Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. , 1998, Genes & development.

[42]  J. Lehmann,et al.  An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). , 1995, The Journal of biological chemistry.

[43]  L. Leon,et al.  Torpor in mice is induced by both leptin-dependent and -independent mechanisms. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Lazar,et al.  Peroxisome proliferator-activated receptor gamma1 expression is induced during cyclic adenosine monophosphate-stimulated differentiation of alveolar type II pneumonocytes. , 1997, Endocrinology.

[45]  M. Lazar,et al.  The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. , 1998, Carcinogenesis.

[46]  R. Evans,et al.  PPAR gamma is required for placental, cardiac, and adipose tissue development. , 1999, Molecular cell.

[47]  Stephen A. Smith,et al.  [[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. , 1994, Journal of medicinal chemistry.

[48]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.

[49]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[50]  H. Green,et al.  Specificity of gene expression in adipocytes , 1985, Molecular and Cellular Biology.

[51]  K. Chien,et al.  PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development , 1999 .

[52]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. , 1994, Cell.

[53]  T. Buchanan,et al.  Metabolic Effects of Troglitazone Monotherapy in Type 2 Diabetes Mellitus , 1998, Annals of Internal Medicine.

[54]  R. Hammer,et al.  Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. , 2000, Molecular cell.

[55]  R. Evans,et al.  Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. , 2000, The Journal of clinical investigation.

[56]  M. Ghazzi,et al.  Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. , 1997 .